Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.69 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | MAOA | P21397 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7374619 | 0.86 | ABCG2 (0.69) | ABCG2ABCC1KDM4EALDH1A1MAOA | |
| SCHEMBL31234378 | 0.85 | KDM4E (0.52) | ABCG2ABCC1KDM4EALDH1A1MAOA | |
| SCHEMBL29129556 | 0.84 | MAOA (0.57) | ABCG2ABCC1KDM4EALDH1A1MAOA | |
| SCHEMBL1534501 | 0.84 | MAOA (0.57) | ABCG2ABCC1KDM4EALDH1A1MAOA | |
| Hydrochloric Acid SCHEMBL31572317 | 0.84 | KDM4E (0.51) | ABCG2ABCC1KDM4EALDH1A1MAOA | |
| SCHEMBL8875406 | 0.82 | ABCG2 (0.64) | ABCG2ABCC1KDM4EALDH1A1LMNA | |
| Acetic Acid SCHEMBL31572318 | 0.81 | KDM4E (0.48) | ABCG2ABCC1KDM4EALDH1A1MAOA | |
| SCHEMBL29993383 | 0.80 | ABCG2 (1.00) | ABCG2ABCC1KDM4EALDH1A1NPC1 | |
| SCHEMBL253523 | 0.80 | ABCG2 (1.00) | ABCG2ABCC1KDM4EALDH1A1NPC1 | |
| SCHEMBL8876901 | 0.80 | ABCG2 (0.62) | ABCG2ABCC1KDM4EALDH1A1CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-9757378-B2 | Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation | UNIVERSITE DE MONTREAL (CA) | 2017-09-12 | — | — | US | disclosed |
| US-20140343051-A1 | METHODS TO MODULATE ACUTE MYELOID LEUKEMIA STEM/PROGENITOR CELL EXPANSION AND/OR DIFFERENTIATION | HOPITAL MAISONNEUVE-ROSEMONT (CA) | 2014-11-20 | — | — | US | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343051-A1 | METHODS TO MODULATE ACUTE MYELOID LEUKEMIA STEM/PROGENITOR CELL EXPANSION AND/OR DIFFERENTIATION | MCL1, AHR, MYADM | ABCG2 549/4885ABCC1 1137/4885KDM4E 1282/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | ABCG2 1606/4885ABCC1 1978/4885KDM4E 1732/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | ABCG2 3622/4885ABCC1 3107/4885KDM4E 2652/4885 |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | ABCG2 3529/4885ABCC1 2072/4885KDM4E 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.